This announcement is a separate document:
四川百利天恒药业股份有限公司自愿披露关于注射用BL-B16D1（双抗ADC）项目治疗晚期实体瘤获得I期临床试验批准通知书的公告
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed the announcement that the injectable BL-B16D1 (dual antibody ADC) program to treat advanced solid tumors obtained an approval letter for phase I clinical trials
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated